Document resource
Introduction Patients with subarachnoid hemorrhage (SAH) have not previously been the focus of studies on intrasaccular aneurysm treatment with the Contour device (Stryker, Kalamazoo, Michigan, USA), which targets complete occlusion at the neck.Aim of Study CONTRA aims at assessing safety and effectiveness of Contour in SAH patients. In this interim analysis, we present preliminary data from the first four participating centers.Method CONTRA is retrospectively collecting available real-world data with independent adjudication by a central imaging core lab (Eppdata, Hamburg, Germany). To achieve the highest possible data quality, rigorous statistical data quality/plausibility checks are used. Several cross-checks are used to ensure complete inclusion of all Contour treated SAH cases.Results Fifty-two SAH patients were enrolled. The aneurysms were treated with Contour alone (32, 62%), in combination with Coils (18, 35%), a stent or a WEB device (each 1, 2%). After Contour placement alone, 73% of aneurysms showed significant stasis, 16% moderate stasis, and 11% complete occlusion. The final procedural occlusion was adequate in 71% (57% RR1 and 14% RR2). Angiographic occlusion rates could be assessed at 6-12 Months in 17 patients (35%). From those, 12/4/1 had RR1/RR2/RR3, respectively (94.1% adequate occlusion). There were 11 patients with improved aneurysm occlusion, no case with worsening. One case of aneurysm re-rupture was observed (2%, 1/52).Abstract LB2 Figure 1Conclusion This interim analysis provides an initial evaluation of the Contour device for treating ruptured aneurysms. Despite methodological limitations, the data supports further exploration of Contour use in SAH. CONTRA will continue collecting data alongside prospective studies.